An open-label study adding creatine monohydrate to ongoing medical regimens in patients with the fibromyalgia syndrome

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 829-836

  Leader, Avi ^a   Amital, Daniella ^a   Rubinow, Alan ^b   Amital, Howard ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c MEIR MEDICAL CENTER   (Israel)

Author keywords

Anxiety; Depression; Fibromyalgia; Pain; Quality of life

Indexed keywords

ANALGESIC AGENT; CREATINE;

ADD ON THERAPY; ADULT; CLINICAL ARTICLE; CLINICAL EVALUATION; COMORBIDITY; CONFERENCE PAPER; DETERIORATION; DIET SUPPLEMENTATION; DISABILITY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DYSTHYMIA; FEMALE; FIBROMYALGIA; FOLLOW UP; HEALTH STATUS; HUMAN; MAJOR DEPRESSION; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PATIENT COMPLIANCE; POSTTRAUMATIC STRESS DISORDER; QUALITY OF LIFE; SELF REPORT; SHORT FORM 36; SLEEP; SLEEP DISORDER; TREATMENT DURATION;

EID: 69949185907     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04811.x     Document Type: Conference Paper

References (32)

1. Buskila, D., F. Atzeni & P. Sarzi-Puttini. 2008. Etiology of fibromyalgia: the possible role of infection and vaccination. Autoimmun. Rev. 8: 41-43.
2. Giesecke, T., R.H. Gracely, D.A. Williams, et al. 2005. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum. 52: 1577-1584.
3. Mountz, J.M., L.A. Bradley, J.G. Modell, et al. 1995. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum. 38: 926-938.
4. Ablin, J.N. & D. Buskila. 2008. Emerging therapies for fibromyalgia. Expert. Opin. Emerg. Drugs 13: 53-62.
5. Sarzi-Puttini, P., D. Buskila, M. Carrabba, et al. 2008. Treatment strategy in fibromyalgia syndrome: where are we now? Semin. Arthritis Rheum. 37: 353-365.
6. Wyss, M. & R. Kaddurah-Daouk. 2000. Creatine and creatinine metabolism. Physiol. Rev. 80: 1107-1213.
7. Persky, A.M. & G.A. Brazeau. 2001. Clinical pharmacology of the dietary supplement creatine mono-hydrate. Pharmacol. Rev. 53: 161-176.
8. Wood, P.B., C.R. Ledbetter, M.F. Glabus, et al. 2009. Hippocampal metabolite abnormalities in fibromyal-gia: correlation with clinical features. J. P a i n 10: 47-52.
9. Dechent, P., P.J. Pouwels, B. Wilken, et al. 1999. Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. Am. J. Physiol. 277: R698-R704.
10. Rae, C., A.L. Digney, S.R. McEwan & T.C. Bates. 2003. Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial. Proc. Biol. Sci. 270: 2147-2150.
11. Amital, D., L. Fostick, M.L. Polliack, et al. 2006. Post-traumatic stress disorder, tenderness, and fibromyal-gia syndrome: are they different entities? J. Psychosom. Res. 61: 663-669.
12. Cohen, H., L. Neumann, Y. Haiman, et al. 2002. Prevalence of post-traumatic stress disorder in fi-bromyalgia patients: overlapping syndromes or post-traumatic fibromyalgia syndrome? Semin. Arthritis Rheum. 32: 38-50.
13. Amital, D., T. Vishne, A. Rubinow & J. Levine. 2006. Observed effects of creatine monohydrate in a patient with depression and fibromyalgia. Am. J. Psychiatry 163: 1840-1841.
14. Amital, D., T. Vishne, S. Roitman, et al. 2006. Open study of creatine monohydrate in treatment-resistant posttraumatic stress disorder. J. Clin. Psychiatry 67: 836-837.
15. Wolfe, F., H.A. Smythe, M.B. Yunus, et al. 1990. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 33: 160-172.
16. Sheehan, D.V., Y. Lecrubier, K.H. Sheehan, et al. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59(Suppl 20): 22-33.
17. Burckhardt, C.S., S.R. Clark & R.M. Bennett. 1991. The fibromyalgia impact questionnaire: development and validation. J. Rheumatol. 18: 728-733.
18. Buysse, D.J., C.F. Reynolds, III, T.H. Monk, et al. 1989. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 28: 193-213.
19. Guy, W. 1976. Clinical global impressions ECDEU assessment manual for psychopharmacol-ogy. ECDEU: National Institute of Health 218-222.
20. Cleeland, C.S. & K.M. Ryan. 1994. Pain assessment: global use of the Brief Pain Inventory. Ann. Acad. Med. Singapore 23: 129-138.
21. Mchorney, C.A., J.E. Ware, Jr. & A.E. Raczek. 1993. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care 31: 247-263.
22. Sheehan, D.V., K. Harnett-Sheehan & B.A. Raj. 1996. The measurement of disability. Int. Clin. Psy-chopharmacol. 11(Suppl 3): 89-95.
23. Dunkl, P.R., A.G. Taylor, G.G. McConnell, et al. 2000. Responsiveness of fibromyalgia clinical trial outcome measures. J. Rheumatol. 27: 2683-2691.
24. Ablin, J.N., Y. Shoenfeld & D. Buskila. 2006. Fi-bromyalgia, infection and vaccination: Two more parts in the etiological puzzle. J. Autoimmun. 27: 145-152.
25. Mease, P.J. & K. Seymour. 2008. Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy? Curr. Pain Headache Rep. 12: 399-405.
26. Birtane, M., K. Uzunca, N. Tastekin & H. Tuna. 2007. The evaluation of quality of life in fibromyalgia syndrome: a comparison with rheumatoid arthritis by using SF-36 Health Survey. Clin. Rheumatol. 26: 679-684.
27. Martinez, J.E., M.B. Ferraz, E.I. Sato & E. Atra. 1995. Fibromyalgia versus rheumatoid arthritis: a longitudinal comparison of the quality of life. J. Rheumatol. 22: 270-274.
28. Burckhardt C.S., S.R. Clark & R.M. Bennett. 1993. Fibromyalgia and quality of life: a comparative analysis. J. Rheumatol. 20: 475-479.
29. Arnold, L.M., Y. Lu, L.J. Crofford, et al. 2004. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 50: 2974-2984.
30. Arnold, L.M., A. Rosen, Y.L. Pritchett, et al. 2005. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fi-bromyalgia with or without major depressive disorder. Pain 119: 5-15.
31. Arnold, L.M., D.L. Goldenberg, S.B. Stanford, et al. 2007. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, mul-ticenter trial. Arthritis Rheum. 56: 1336-1344.
32. Arnold, L.M., Y. Lu, L.J. Crofford, et al. 2004. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 50: 2974-2984